OKUR Stock Price | OnKure Therapeutics, Inc. P/E, Revenue, EPS, & Forecasts

OnKure Therapeutics, Inc. • OKUR

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About OnKure Therapeutics, Inc.

Ticker

OKUR

Trading on

NASDAQ

ISIN

US68277Q1058

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Nicholas A. Saccomano Ph.D.

Headquarters

6707 Winchester Circle, Boulder, CO, United States, 80301

Employees

Website

https://onkuretherapeutics.com

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.

Metrics

BasicAdvanced

Market cap

$35.5M

P/E ratio

EPS

-$4.68

Dividend Yield

0.00%

Beta

Forward P/E ratio

EBIDTA

$-66.2M

Ex dividend date

Price & volume

Market cap

$35.5M

Average daily volume

0.2M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

0.53

Earnings

EPS

-$4.68

EPS estimate (current quarter)

-$1.17

EPS estimate (next quarter)

-$1.07

EBITDA

$-66.2M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

52-week High

$15.89

52-week Low

$1.70

50-day moving average

$2.94

200-day moving average

$3.01

Short ratio

0.26

Short %

0.39%

Management effectiveness

ROE (TTM)

-207.36%

ROA (TTM)

-96.53%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

12.9M

Float

Insiders %

1.73%

Institutions %

86.38%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 6 analysts.

Average price target

$27.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$1.37

-$0.87

-57.47%

Q4 • 24Missed

-$1.19

-$1.38

14.04%

Q1 • 25Beat

-$1.14

-$1.25

8.65%

Q2 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-15.4M

-∞%

Q2 • 25

$0M

$-14.7M

-∞%

Q3 • 25

NaN%

-4.49%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$86.1M

$7.9M

9.18%

Q2 • 25

$72.8M

$6.4M

8.80%

Q3 • 25

-15.38%

-18.94%

-4.21%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-13.3M

$-0M

$0M

$-13.3M

Q2 • 25

$-13M

$-0M

$0M

$-13M

Q3 • 25

-1.79%

-53.85%

NaN%

-1.84%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a OnKure Therapeutics, Inc. share?

OnKure Therapeutics, Inc. shares are currently traded for undefined per share.

How many shares does OnKure Therapeutics, Inc. have?

OnKure Therapeutics, Inc. currently has 12.9M shares.

Does OnKure Therapeutics, Inc. pay dividends?

No, OnKure Therapeutics, Inc. doesn't pay dividends.

What is OnKure Therapeutics, Inc. 52 week high?

OnKure Therapeutics, Inc. 52 week high is $15.89.

What is OnKure Therapeutics, Inc. 52 week low?

OnKure Therapeutics, Inc. 52 week low is $1.70.

What is the 200-day moving average of OnKure Therapeutics, Inc.?

OnKure Therapeutics, Inc. 200-day moving average is $3.01.

Who is OnKure Therapeutics, Inc. CEO?

The CEO of OnKure Therapeutics, Inc. is Dr. Nicholas A. Saccomano Ph.D..

How many employees OnKure Therapeutics, Inc. has?

OnKure Therapeutics, Inc. has 46 employees.

What is the market cap of OnKure Therapeutics, Inc.?

The market cap of OnKure Therapeutics, Inc. is $35.5M.

What is the P/E of OnKure Therapeutics, Inc.?

The current P/E of OnKure Therapeutics, Inc. is null.

What is the EPS of OnKure Therapeutics, Inc.?

The EPS of OnKure Therapeutics, Inc. is -$4.68.

What is the PEG Ratio of OnKure Therapeutics, Inc.?

The PEG Ratio of OnKure Therapeutics, Inc. is null.

What do analysts say about OnKure Therapeutics, Inc.?

According to the analysts OnKure Therapeutics, Inc. is considered a buy.